Qiagen's HC2 More Effective Than Pap Test In Preventing Cancer - Study

Qiagen/Digene's Hybrid Capture 2 human papillomavirus (HPV) DNA test is more effective than Pap testing alone in preventing cervical cancer, according to the results of a large-scale study published online Jan. 19 in The Lancet Oncology

More from Archive

More from Medtech Insight

Thena Capital’s New Fund Up And Running With £1M Investment In Plexāā’s Breast Cancer Device

 

Thena Capital, the first UK-based early-stage specialist medtech firm, has made its first investment since closing its £50m fund. Medtech Insight spoke with general partner Pamela Walker Geddes to gain insight into Thena Capital’s investment strategy.

Execs On The Move: June 23–27, 2025

 
• By 

An interactive look at recent executive-level company changes and promotions in the medical device and diagnostics industries.

Court Orders US FDA To Return Trial Diversity Action Plan Guidance To Website

 
• By 

HHS and its agencies violated the law by swiftly implementing “sweeping and poorly thought-through directives that ordered the bulk removal of healthcare resources,” including FDA draft guidances on diversity action plans and sex differences in clinical trials, a federal court said.